title: Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli.
abstract: DNA sequencing data showed that five clinical isolates of Escherichia coli with reduced susceptibility to ceftazidime, ceftriaxone, and cefotaxime contain an ampC gene that is preceded by a strong promoter. Transcription from the strong promoter was 8- to 18-fold higher than that from the promoter from a susceptible isolate. RNA studies showed that mRNA stability does not play a role in the control of AmpC synthesis.
authors: Department of Medical Microbiology, University of Cape Town, South Africa.
authors: E C
authors: EC
authors: Nelson
authors: B G
authors: BG
authors: Elisha
mesh_terms: D001483:Base Sequence; D002442:Ceftazidime / Q000494:pharmacology; D018550:Cephalosporin Resistance / Q000235:genetics*; D004926:Escherichia coli / Q000235:genetics*; D015964:Gene Expression Regulation, Bacterial; D005798:Genes, Bacterial / Q000235:genetics* / Q000502:physiology; D006801:Humans; D008969:Molecular Sequence Data; D009692:Nucleic Acid Heteroduplexes; D012333:RNA, Messenger / Q000378:metabolism; D012045:Regulatory Sequences, Nucleic Acid / Q000235:genetics; D017422:Sequence Analysis, DNA; D012689:Sequence Homology, Nucleic Acid
chemical_list: D009692:Nucleic Acid Heteroduplexes; D012333:RNA, Messenger; D002442:Ceftazidime